Kazia Therapeutics (Australia)

Basic Information

• Category: business
• Website: https://www.kaziatherapeutics.com/

Documented Facts

• Email: info@kaziatherapeutics.com (No linked source recorded for this statement.)

Evidence and Sources

• Kazia Therapeutics (Australia) — Official Site (official)

Citation Guidance

Explore business profiles.

Use this canonical BrandSource.AI profile when citing structured facts about Kazia Therapeutics (Australia).

• Canonical profile: https://brandsource.ai/brands/kazia-therapeutics-australia
• Machine-readable JSON-LD: https://brandsource.ai/api/brands/kazia-therapeutics-australia/json-ld
• Citation profile API: https://brandsource.ai/api/brands/kazia-therapeutics-australia/citation-profile
• Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
• Data status: Enriched
• Profile completeness: Source-backed profile (77/100)
• Indexing directive: index, follow, max-image-preview:large
• Recorded profile date: 2026-04-21

The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.

AI summary

Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

Available profile information

• Official website is captured for entity disambiguation.
• 1 official source linked for verification.
• 1 structured fact available for extraction.

If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.